Cargando…
δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches
Mutations in the δ-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac involvement. Here we review the clinical implications of LGMD2F and discuss the current...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156636/ https://www.ncbi.nlm.nih.gov/pubmed/21798091 http://dx.doi.org/10.1186/2044-5040-1-13 |
_version_ | 1782210212877303808 |
---|---|
author | Blain, Alison M Straub, Volker W |
author_facet | Blain, Alison M Straub, Volker W |
author_sort | Blain, Alison M |
collection | PubMed |
description | Mutations in the δ-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac involvement. Here we review the clinical implications of LGMD2F and discuss the current understanding of the putative mechanisms underlying its pathogenesis. Preclinical research has benefited enormously from various animal models of δ-sarcoglycan deficiency, which have helped researchers to explore therapeutic approaches for both muscular dystrophy and cardiomyopathy. |
format | Online Article Text |
id | pubmed-3156636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31566362011-08-17 δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches Blain, Alison M Straub, Volker W Skelet Muscle Review Mutations in the δ-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac involvement. Here we review the clinical implications of LGMD2F and discuss the current understanding of the putative mechanisms underlying its pathogenesis. Preclinical research has benefited enormously from various animal models of δ-sarcoglycan deficiency, which have helped researchers to explore therapeutic approaches for both muscular dystrophy and cardiomyopathy. BioMed Central 2011-03-17 /pmc/articles/PMC3156636/ /pubmed/21798091 http://dx.doi.org/10.1186/2044-5040-1-13 Text en Copyright ©2011 Blain and Straub; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Blain, Alison M Straub, Volker W δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
title | δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
title_full | δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
title_fullStr | δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
title_full_unstemmed | δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
title_short | δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
title_sort | δ-sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156636/ https://www.ncbi.nlm.nih.gov/pubmed/21798091 http://dx.doi.org/10.1186/2044-5040-1-13 |
work_keys_str_mv | AT blainalisonm dsarcoglycandeficientmusculardystrophyfromdiscoverytotherapeuticapproaches AT straubvolkerw dsarcoglycandeficientmusculardystrophyfromdiscoverytotherapeuticapproaches |